Mefenamic Acid

Introduction Overview

Generic Name

mefenamic acid

Brand Name

Ponstel

Dosage Form

oral capsule (250 mg)

Drug Class

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Pharmacokinetics

Absorption:
Mefenamic acid is well absorbed after oral administration, with peak plasma concentrations typically reached within 2 to 4 hours. Despite its rapid absorption, food intake can delay the peak plasma concentration but does not significantly reduce the extent of absorption. The bioavailability of mefenamic acid is generally high, facilitating effective systemic concentrations for the treatment of pain and inflammation. Clinical studies indicate that mefenamic acid is suitable for short-term use due to its pharmacokinetic profile.

Distribution:
Following absorption, mefenamic acid is extensively bound to plasma proteins, approximately 90-99%, primarily albumin. This high protein binding limits its free plasma concentration but also influences its volume of distribution, which tends to be moderate. The drug readily distributes into synovial fluid, which is advantageous for its anti-inflammatory effects in joints and menstrual tissues. Distribution to other tissues, including crossing the placenta, has been observed, which contributes to its warnings during pregnancy.

Metabolism:
Mefenamic acid undergoes extensive hepatic metabolism, primarily via cytochrome P450 enzymes, including CYP2C9. The metabolic process converts mefenamic acid into hydroxylated and conjugated inactive metabolites, which are less pharmacologically active. The metabolic rate can be influenced by liver function status and concomitant use of drugs that induce or inhibit cytochrome P450 enzymes. Because of extensive first-pass metabolism, variation in hepatic enzyme activity can affect plasma drug levels.

Elimination:
Elimination of mefenamic acid primarily occurs through renal excretion after metabolic conversion. About 65-90% of the administered dose is excreted in the urine within 48 hours, mainly as hydroxylated metabolites and their conjugates; less than 1% is found unchanged. The plasma elimination half-life ranges from 2 to 4 hours, supporting dosing every 6 hours as clinically recommended. Renal impairment can prolong elimination, necessitating caution or dose adjustment in such patients. Fecal excretion accounts for a smaller portion of elimination. Clinical implications include careful monitoring for toxicity, especially with prolonged use or in patients with compromised renal or hepatic function.

Dosage Forms

Available Dosage Forms:
Mefenamic acid is formulated primarily as oral capsules containing 250 mg of the active ingredient. This solid dosage form is designed for systemic absorption and is suitable for adults and adolescents aged 14 years and older.

Dosages for Adults and Adolescents:
- For the relief of acute mild to moderate pain: Initial dose of 500 mg orally once, followed by 250 mg every 6 hours as needed, not to exceed 7 days of treatment.
- For treatment of primary dysmenorrhea: Initial dose of 500 mg orally once at the onset of bleeding and pain, followed by 250 mg every 6 hours as needed for 2 to 3 days.
- Pediatric patients 14 years or older receive dosing similar to adults.

Specific Patient Populations:
- The drug is not approved for children younger than 14 years.
- Use in elderly patients requires caution due to increased risk of gastrointestinal bleeding and renal impairment.
- Not recommended during pregnancy, especially during the last 20 weeks, because of potential fetal cardiovascular and renal toxicity.
- Use in patients with impaired liver or renal function should be cautious; monitoring and dose adjustments may be necessary.

Clinical Guidelines:
- Short-term usage is emphasized, generally not exceeding 7 days to minimize adverse events.
- Lowest effective dose should be used.
- Patients should follow dosing instructions carefully and avoid overlapping use with other NSAIDs.

Mechanism Of Action

Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) that exerts its primary effect through inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These enzymes catalyze the conversion of arachidonic acid to prostaglandins, which are lipid compounds involved in pain, inflammation, and fever. By suppressing prostaglandin synthesis, mefenamic acid reduces the production of mediators that sensitize nerve endings and contribute to the inflammatory process.

At the cellular level, mefenamic acid's inhibition of prostaglandin formation results in decreased vasodilation, reduced edema, and attenuation of leukocyte activation and migration to sites of inflammation. Its effect on prostaglandins also contributes to decreased uterine smooth muscle contractions, which underlies its efficacy in relieving menstrual cramps (dysmenorrhea).

Biochemically, mefenamic acid's NSAID properties also affect platelet function due to reduced thromboxane A2 synthesis; however, its antiplatelet effect is less pronounced and shorter-lived compared to aspirin. The drug’s nonselective inhibition of COX enzymes accounts for both therapeutic benefits and potential adverse effects, including gastrointestinal irritation and risk of bleeding.

Comparative studies demonstrate that mefenamic acid has similar mechanisms to other NSAIDs like ibuprofen and naproxen but differs in pharmacokinetics and side effect profiles. Its use is primarily for short-term treatment due to its safety considerations. Clinical research supports its use for acute pain and dysmenorrhea, with efficacy comparable to other NSAIDs but with a distinct dosing schedule influenced by its half-life.

Pharmacological Actions

Inhibition of cyclooxygenase-1 and cyclooxygenase-2 enzymes leading to decreased prostaglandin production.
Anti-inflammatory effects by reducing vascular permeability and leukocyte infiltration at sites of inflammation.
Analgesic action through reduction of prostaglandin-mediated sensitization of nociceptors.
Antipyretic effects by acting on the hypothalamic thermoregulatory center to reduce fever.
Reduction of uterine muscle contractions, providing relief from menstrual cramps (primary dysmenorrhea).
Moderate antiplatelet activity through thromboxane A2 inhibition, contributing to effects on hemostasis.
Rapid onset of action suitable for acute pain management.
Short elimination half-life allowing dosing every 6 hours.
Nonselective COX inhibition accounting for both therapeutic and adverse effects.
High protein-binding affecting distribution and interaction with other drugs.
Metabolism predominantly via hepatic cytochrome P450 enzymes (especially CYP2C9).
Renal excretion of metabolites indicating the need for caution in renal impairment.
Potential to cause gastric mucosal irritation by reducing protective prostaglandins in the GI tract.
Effectiveness enhanced by starting treatment at onset of symptoms, particularly in dysmenorrhea.
Limited use for short durations to mitigate risk of cardiovascular and gastrointestinal adverse events.

Therapeutic Or Clinical Uses

Relief of mild to moderate acute pain in adults and adolescents aged 14 years and older.
Treatment of primary dysmenorrhea (menstrual pain) to reduce cramps and associated discomfort.
Management of musculoskeletal pain where NSAIDs are indicated for short-term use.
Use in acute inflammatory states where reduction of prostaglandin-mediated symptoms is desired.
Short-term analgesic management after minor surgical procedures.
Alternative NSAID choice for patients intolerant to other NSAIDs after appropriate evaluation.
Relief of pain associated with dental procedures or minor trauma.
Potential off-label use in other painful conditions as prescribed by healthcare providers.
Symptomatic management of pain accompanied by inflammation.
Use as part of multimodal pain management strategies to reduce opioid requirements.
Therapeutic option when rapid onset of pain relief is required.
Treatment limited to periods not exceeding 7 days to reduce adverse event risk.
Employed in clinical settings where NSAID-induced platelet effects are acceptable.
Use guided by evaluation of individual cardiovascular, renal, and gastrointestinal risk factors.
Preferred choice for dysmenorrhea treatment initiated at the onset of menstrual bleeding.

Side Or Adverse Effects

Gastrointestinal irritation including heartburn, stomach pain, gas, nausea, and vomiting.
Diarrhea and constipation as common gastrointestinal side effects.
Dizziness and headache occurring in some patients.
Risk of serious gastrointestinal bleeding, especially with prolonged use or in the elderly.
Allergic reactions ranging from mild skin rash to severe anaphylaxis.
Serious skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Signs of liver toxicity such as jaundice, dark urine, itching, and upper right abdominal pain.
Renal impairment presenting with decreased urine output, swelling, and fatigue.
Fluid retention and edema potentially exacerbating hypertension and heart failure.
Anemia and other hematologic abnormalities due to bleeding or bone marrow effects.
Cardiovascular risks including increased incidence of fatal heart attack and stroke.
Increased risk of bleeding due to platelet function interference.
Potential for drug-induced hypersensitivity reactions in patients with asthma or aspirin intolerance.
Gastrointestinal ulceration and perforation, sometimes fatal.
Central nervous system effects such as confusion and somnolence in rare cases.

Precautions

Use the lowest effective dose for the shortest duration possible to minimize risks.
Avoid use in patients with history of allergic reaction to NSAIDs or aspirin.
Caution in patients with pre-existing gastrointestinal disorders including ulcers and bleeding.
Monitor for signs of gastrointestinal bleeding or perforation during treatment.
Avoid use in patients with active liver or kidney disease unless benefit outweighs risk.
Careful consideration in patients with cardiovascular disease, hypertension, or risk factors.
Not recommended during the last 20 weeks of pregnancy due to fetal risks.
Avoid concomitant use with other NSAIDs or anticoagulants unless prescribed by a physician.
Patients with asthma or history of NSAID-induced bronchospasm should avoid use.
Use with caution in elderly patients due to increased risk of adverse effects.
Patients should be monitored for fluid retention and exacerbation of heart failure.
Avoid alcohol consumption to reduce risk of gastric irritation and bleeding.
Adjust dosing or avoid use in patients with impaired renal or hepatic function.
Patients should report any signs of allergic reactions, skin changes, or unusual bruising promptly.
Inform healthcare providers of all concomitant medications to avoid drug interactions.

Warnings

Mefenamic acid increases the risk of fatal myocardial infarction and stroke, even in patients without prior cardiovascular disease.
Avoid use immediately before or after coronary artery bypass graft (CABG) surgery.
Potential for fatal gastrointestinal bleeding, ulceration, and perforation, especially with prolonged use.
Serious skin reactions have been reported; discontinue immediately if rash or mucosal lesions develop.
Use during pregnancy, particularly beyond 20 weeks’ gestation, may cause fetal cardiovascular and renal harm.
Do not use in patients with active gastrointestinal bleeding or peptic ulcer disease.
Risk of renal impairment and acute renal failure especially in patients with underlying kidney disease.
May cause fluid retention and exacerbate hypertension or congestive heart failure.
Possibility of hypersensitivity reactions including bronchospasm in susceptible individuals.
Long-term use increases risks of adverse cardiovascular and gastrointestinal events.
Use with caution when combined with anticoagulants or other medications affecting hemostasis.
Premature discontinuation of therapy can lead to rebound pain; adhere to dosing schedule.
Avoid concomitant use with other NSAIDs or high-dose aspirin to minimize bleeding risk.
Notify healthcare providers of all medications to prevent harmful interactions.
Promptly seek emergency medical attention for symptoms of heart attack, stroke, or severe allergic reaction.

Contraindication

Known hypersensitivity or allergy to mefenamic acid or other NSAIDs.
Active peptic ulcer or gastrointestinal bleeding.
History of NSAID-induced asthma, urticaria, or allergic-type reactions.
Severe renal insufficiency or significant kidney disease.
Severe hepatic impairment or liver failure.
During the third trimester of pregnancy, especially after 20 weeks gestation.
Patients who have experienced anaphylaxis or severe hypersensitivity to aspirin or NSAIDs.
Bowel disorders such as ulcerative colitis or inflammatory bowel disease with active symptoms.
Immediately before or after coronary artery bypass graft surgery (CABG).
Patients with bleeding disorders or coagulopathies.
Concomitant use with other NSAIDs contraindicates combined therapy due to increased adverse effects.
Patients with uncontrolled hypertension or congestive heart failure where NSAIDs are to be avoided.
Pediatric patients younger than 14 years due to lack of established safety and efficacy.
History of severe skin reactions like Stevens-Johnson syndrome related to NSAID use.
Concurrent use with certain drugs posing risk of drug interactions contraindicates mefenamic acid.

Drug Interactions

Concurrent use with anticoagulants (e.g., warfarin) increases bleeding risk.
Combination with other NSAIDs or aspirin may potentiate adverse gastrointestinal and renal effects.
Co-administration with lithium can increase lithium plasma levels and toxicity.
Methotrexate levels can be raised by mefenamic acid, leading to enhanced toxicity.
Use with corticosteroids like prednisone increases risk of gastrointestinal ulceration and bleeding.
Antihypertensive agents, including diuretics, may have reduced efficacy when used with mefenamic acid.
Certain antidepressants (SSRIs, SNRIs) combined with mefenamic acid can increase bleeding tendency.
Antacids such as magnesium or aluminum-containing products may alter absorption or binding.
Potential pharmacokinetic interactions occur via cytochrome P450 enzymes, especially CYP2C9 inhibitors or inducers.
Concurrent use with nephrotoxic drugs increases risk of renal impairment.
Co-administration with antiplatelet agents elevates bleeding risk.
NSAIDs can interfere with the efficacy of certain antihypertensives like ACE inhibitors and beta blockers.
Use with digoxin may increase digoxin levels due to renal clearance interference.
Potential interaction with oral hypoglycemics may alter glucose control.
Increased risk of toxicity or altered effects when combined with herbal supplements affecting coagulation.

Preparations Of The Drug

Oral capsule containing 250 mg mefenamic acid as the active ingredient.
Available commercially under the brand name Ponstel.
Formulated as hard gelatin capsules designed for oral administration.
Packaged in bottles to maintain stability and protect from moisture and heat.
No liquid or alternative dosage forms widely approved or marketed.
Manufactured to meet pharmaceutical quality standards ensuring accurate dosing.
Contains inactive excipients to enhance bioavailability and stability.
Intended for short-term use with labeling including dosage instructions and warnings.
Supplied with patient medication guides to advise on risks and proper usage.
Available in prescription-only formulations reflecting its usage and safety profile.
Packaging includes tamper-evident seals and child-resistant caps for safety.
Storage recommendations advise room temperature conditions away from moisture.
Batch testing ensures potency and purity for safe clinical application.
Preparations meet regulatory standards imposed by health authorities like FDA.
No topical, injectable, or extended-release formulations currently authorized.